Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination
暂无分享,去创建一个
N. Pantazis | A. Hatzakis | A. Karabinis | S. Tsiodras | D. Paraskevis | V. Sypsa | M. Psichogiou | I. Pavlopoulou | K. Petsios | A. Chaidaroglou | D. Degiannis | S. Roussos
[1] S. Zeger,et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression , 2022, The Lancet.
[2] J. Mascola,et al. Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization , 2021, medRxiv.
[3] P. Schommers,et al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant , 2021, Nature Medicine.
[4] M. Nussenzweig,et al. Plasma neutralization properties of the SARS-CoV-2 Omicron variant , 2021, medRxiv.
[5] J. Kimpel,et al. SARS-CoV-2 B.1.1.529 variant (Omicron) evades neutralization by sera from vaccinated and convalescent individuals , 2021, medRxiv.
[6] R. Arbel,et al. BNT162b2 Vaccine Booster and Mortality Due to Covid-19 , 2021, The New England journal of medicine.
[7] Michael I. Mandel,et al. Protection against Covid-19 by BNT162b2 Booster across Age Groups , 2021, The New England journal of medicine.
[8] M. Hernán,et al. Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans , 2021, New England Journal of Medicine.
[9] Lindsay N. Carpp,et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial , 2021, Science.
[10] J. Lopez Bernal,et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. Reply. , 2021, The New England journal of medicine.
[11] A. Yavlinsky,et al. Waning of SARS-CoV-2 antibodies targeting the Spike protein in individuals post second dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and risk of breakthrough infections: analysis of the Virus Watch community cohort. , 2021, medRxiv.
[12] L. Abu-Raddad,et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar , 2021, Nature Medicine.
[13] A. Milstone,et al. Durability of Antibody Levels After Vaccination With mRNA SARS-CoV-2 Vaccine in Individuals With or Without Prior Infection. , 2021, JAMA.
[14] L. Abu-Raddad,et al. Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar. , 2021, JAMA.
[15] M. Davenport,et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis , 2021, The Lancet Microbe.
[16] Michael I. Mandel,et al. Waning Immunity after the BNT162b2 Vaccine in Israel , 2021, The New England journal of medicine.
[17] R. Rappuoli,et al. Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants , 2021, Nature.
[18] K. Schmader,et al. Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents? , 2021, Aging Clinical and Experimental Research.
[19] R. Baric,et al. Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines , 2021, The New England journal of medicine.
[20] Y. Kreiss,et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months , 2021, The New England journal of medicine.
[21] M. Hernán,et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study , 2021, The Lancet.
[22] O. A. Ogun,et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study , 2021, The Lancet.
[23] J. Mascola,et al. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase , 2021, The New England journal of medicine.
[24] M. Nussenzweig,et al. High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape , 2021, Nature.
[25] J. Mascola,et al. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates , 2021, Science.
[26] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months , 2021, The New England journal of medicine.
[27] E. Walsh,et al. SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3 , 2021, The New England journal of medicine.
[28] J. Dogné,et al. Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers , 2021, Vaccines.
[29] K. Syrigos,et al. Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection , 2021, Vaccines.
[30] L. Tserel,et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study , 2021, The Lancet Regional Health - Europe.
[31] L. Abu-Raddad,et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar , 2021, medRxiv.
[32] J. Mascola,et al. Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants , 2021, Science.
[33] A. Kaneda,et al. Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan , 2021, Clinical Microbiology and Infection.
[34] M. Lipsitch,et al. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers , 2021, The New England journal of medicine.
[35] R. Myers,et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant , 2021, The New England journal of medicine.
[36] M. C. Muenker,et al. Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity , 2021, Nature.
[37] A. Huppert,et al. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers , 2021, The Lancet Respiratory Medicine.
[38] Frances E. Muldoon,et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 , 2021, Nature.
[39] J. Vekemans,et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection , 2021, Nature Medicine.
[40] C. Rice,et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection , 2021, Nature.
[41] G. Ciliberto,et al. Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine , 2021, EClinicalMedicine.
[42] P. Dormitzer,et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans , 2021, Nature.
[43] M. Davenport,et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.
[44] J. Mascola,et al. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 , 2021, The New England journal of medicine.
[45] K. Mounzer,et al. Weight gain before and after switch from TDF to TAF in a U.S. cohort study , 2021, Journal of the International AIDS Society.
[46] T. de Oliveira,et al. New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications , 2021, The New England journal of medicine.
[47] A. Fiore-Gartland,et al. Evidence for antibody as a protective correlate for COVID-19 vaccines , 2021, Vaccine.
[48] H. Schaal,et al. Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination , 2021, medRxiv.
[49] J. Mascola,et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.
[50] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.
[51] D. Lauffenburger,et al. Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.
[52] J. Bloom,et al. Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with high attack rate , 2020, medRxiv.
[53] A. Handel,et al. Heterogeneity and longevity of antibody memory to viruses and vaccines , 2018, PLoS biology.
[54] P. Offit,et al. Plotkin's Vaccines , 2017 .
[55] N. Xia,et al. Modeling the long-term antibody response of a hepatitis E vaccine. , 2015, Vaccine.
[56] Edward L. Korn,et al. Analysis of Health Surveys , 1999 .
[57] S. E. Hills,et al. Illustration of Bayesian Inference in Normal Data Models Using Gibbs Sampling , 1990 .
[58] J. Ware,et al. Random-effects models for longitudinal data. , 1982, Biometrics.